Clinical Trials
3 trialsNCT02805660 2021-04-06
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mirati Therapeutics Inc.
Phase 1/2 Terminated
NCT00324220 2015-07-01
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Mirati Therapeutics Inc.
Phase 1/2 Completed
NCT00372437 2015-07-01
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Mirati Therapeutics Inc.
Phase 1/2 Completed